RxDoctor Payments Data

Brittany Weber

Cardiovascular Disease · Dallas, TXNPI 1730527227

Payments from drug & device makers

$186,475in general payments, 2019–2025

Across 104 payments — averaging $1793.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$99K
  • Novo Nordisk$44K
  • E.r. Squibb & Sons, L.L.C.$19K
  • Kiniksa Pharmaceuticals, Ltd.$14K
  • Amgen$5K
  • Kiniksa Pharmaceuticals International, PLC$2K
  • plus $2K from 6 others

What the payments were for

  • Consulting fees$118,87264%
  • Speaking & faculty fees$15,1558%
  • Travel & lodging$46,25725%
  • Food & beverage$4,8113%
  • Education$1,3811%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$186,475 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$80,691
Medicare patients
1,346
Services billed
1,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArcalystRilonacept13$296,278
EliquisApixaban24$29,571
WegovySemaglutide17$22,008
Repatha SureclickEvolocumab15$20,669
Praluent PenAlirocumab20$18,688
JardianceEmpagliflozin17$15,696
NexletolBempedoic Acid11$5,987
Rosuvastatin Calcium197$4,729
Colchicine29$2,579
Ezetimibe53$1,822
Metoprolol Succinate67$1,151
Losartan Potassium33$368
Atorvastatin Calcium32$293
ClopidogrelClopidogrel Bisulfate16$229
Amlodipine Besylate54$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kiniksa Pharmaceuticals International, PLCArcalyst$2,400$296,27813 claims
PfizerEliquis$101$29,57124 claims
Novo NordiskWegovy$44,472$22,00817 claims
Esperion Therapeutics, Inc.Nexletol$1,816$5,98711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →